Edition:
United Kingdom

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

32.56USD
19 Jul 2018
Change (% chg)

$-0.32 (-0.97%)
Prev Close
$32.88
Open
$32.76
Day's High
$32.76
Day's Low
$32.13
Volume
1,356
Avg. Vol
33,948
52-wk High
$39.67
52-wk Low
$20.27

Latest Key Developments (Source: Significant Developments)

Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Albireo Pharma Inc ::ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS.ALBIREO PHARMA INC - ELOBIXIBAT APPROVED IN JAPAN FOR TREATMENT OF CHRONIC CONSTIPATION.ALBIREO PHARMA - JAPAN'S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN.ALBIREO PHARMA INC - APPROVAL OF ELOBIXIBAT IN JAPAN TRIGGERS PAYMENTS TO ALBIREO SUBSIDIARY ELOBIX AB FROM EA PHARMA CO LTD.ALBIREO PHARMA - CO ‍EXPECTS TO INITIATE A PLANNED PHASE 3 STUDY OF A4250 BY SPRING OF 2018​.  Full Article

Albireo Announces Agreement With Healthcare Royalty Partners
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN.ALBIREO PHARMA INC - ‍ALBIREO SUBSIDIARY ELIGIBLE TO RECEIVE UP TO $60 MILLION UNDER AGREEMENT​.ALBIREO PHARMA INC - ‍DECISION ON JAPANESE NEW DRUG APPLICATION FOR ELOBIXIBAT EXPECTED IN FIRST HALF OF 2018​.ALBIREO PHARMA -HCR OBTAINS RIGHT TO RECEIVE ROYALTIES, SALES MILESTONES FOR ELOBIXIBAT IN JAPAN THAT MAY BE PAYABLE BY EA PHARMA, UP TO A THRESHOLD​.ALBIREO PHARMA INC - ‍ELOBIX HAS RETAINED ITS RIGHT TO RECEIVE A MILESTONE PAYMENT FROM EA PHARMA IF ELOBIXIBAT IS APPROVED BY MHLW​.ALBIREO PHARMA INC - ‍ IF SPECIFIED THRESHOLD IS REACHED, ELOBIX WILL AGAIN BECOME ELIGIBLE TO RECEIVE ROYALTIES AND SALES MILESTONES FOR ELOBIXIBAT.  Full Article

Albireo posts Q3 loss per share $0.73‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Albireo Pharma Inc :Albireo reports third quarter 2017 financial results.Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​.Albireo Pharma Inc - ‍revenue totaled $0 for Q3 of 2017 compared with $28,000 for Q3 of 2016​.Albireo Pharma Inc - qtrly loss per share $0.73‍​.Albireo Pharma - ‍expects current cash resources will meet operating requirements till end of 2019, assuming receipt of payment from EA Pharma in 2018​.  Full Article

Albireo Pharma files for mixed shelf of up to $125 million‍​
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Albireo Pharma Inc :Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing‍​ ‍​.  Full Article

Biodel Q3 net loss $3.1 million
Thursday, 11 Aug 2016 

Biodel Inc : Biodel reported a net loss of $3.1 million, or $0.05 per share, for quarter ended June 30, 2016 .Biodel reports third quarter fiscal year 2016 financial results.  Full Article

BRIEF-Albireo Pharma Inc Files For Non-Timely 10-K ‍​

* ALBIREO PHARMA INC FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC ‍​ Source text: (http://bit.ly/2pobWiJ) Further company coverage: